4basebio (LON:4BB) Price Target Cut to GBX 1,400 by Analysts at Royal Bank Of Canada

4basebio (LON:4BB) had its price objective decreased by Royal Bank Of Canada from GBX 1,600 to GBX 1,400 in a research note published on Monday morning,Digital Look reports. Royal Bank Of Canada currently has an outperform rating on the stock.

4basebio Price Performance

Shares of LON 4BB traded down GBX 25 during mid-day trading on Monday, reaching GBX 500. 1,239 shares of the company traded hands, compared to its average volume of 1,727. 4basebio has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 1,040. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The firm has a market cap of £77.43 million, a PE ratio of -4.59 and a beta of 1.09. The stock has a fifty day simple moving average of GBX 502.12 and a 200-day simple moving average of GBX 554.32.

4basebio (LON:4BB) last posted its quarterly earnings results on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The business had revenue of GBX 169 million for the quarter. Equities research analysts anticipate that 4basebio will post -3.43 EPS for the current fiscal year.

Insider Transactions at 4basebio

In other news, insider Amy Walker acquired 1,863 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of GBX 509 per share, for a total transaction of £9,482.67. Insiders own 12.09% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.